The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control over 6 months.

Sam Altman and his husband have reportedly invested in a gene-editing startup which aims to eliminate hereditary diseases ...

New research shows that depression beginning before age 25 has a much stronger hereditary component than depression that ...

There are different variations of this, Sachin M. Shridharani, MD, a board-certified plastic surgeon in New York City, tells ...

Silicon Valley billionaires love to chase extreme health tech. Their next obsession, after dabbling in tech to reverse aging, ...

From Kris Jenner's 70th birthday party to Simone Biles opening up about getting breast implants, these are the buzziest style ...

"I feel like nowadays with social media, you see everyone and you're like, 'Oh my God, how does she look so good?' Social ...

“The way things are going, we will see the end of Pacific herring in our territory,” said Chief Eric Pelkey of the W̱SÁNEĆ ...

Pet insurance—once the province of dusty brochures at the vet’s office—has gone mainstream. But do you really need it?

The day after Prime Minister Mark Carney announced two B.C. additions to the federal government’s list of possible project ...

Prime Minister Mark Carney says his list of major projects has received support from some Indigenous groups, but more will be ...

Investing.com -- Ionis Pharmaceuticals Inc (NASDAQ:IONS) stock rose 3.1% on Friday following a positive regulatory development for its hereditary angioedema treatment in Europe.